aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
pharma · Pulmonary Embolism · Carcinoma, Hepatocellular
Bayer HealthCare Animal
Bayer HealthCare AG
Bayer HealthCare Animal drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us HQ
1919 Founded
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us
- Founded
- 1919
- Employees
- 8
- Programs
- 34
- Drugs
- 32
- Patents
- 24
Bayer HealthCare Animal pipeline
Portfolio lens on 32 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bayer HealthCare Animal drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.
- Target
- Prostaglandin E2 receptor EP1 subtype
- Mechanism
- Prostanoid EP1 receptor agonist
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.
- Target
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
- Mechanism
- PI3-kinase p110-delta subunit inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bayer HealthCare Animal's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
finerenone
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
larotrectinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bayer HealthCare Animal's portfolio. Molecular target: Neurotrophic tyrosine kinase receptor.
- Target
- Neurotrophic tyrosine kinase receptor
- Mechanism
- Neurotrophic tyrosine kinase receptor inhibitor
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
radium ra223 dichloride
Various (V10)Various (V10) compound in Bayer HealthCare Animal's portfolio. Mechanism: Radiotherapy agent.
- Mechanism
- Radiotherapy agent
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
-
regorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.
- Target
- Discoidin domain-containing receptor 2
- Mechanism
- Fibroblast growth factor receptor 2 inhibitor
-
rivaroxaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
US regulatory status: approved.
-
sorafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bayer HealthCare Animal's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor beta.
- Target
- Platelet-derived growth factor receptor beta
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Bayer HealthCare Animal in public FDA and regional records.
-
tedizolid phosphate
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor